Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Regulation Headaches From Morocco To Pakistan

Executive Summary

Delegates at the recent pre-ICDRA conference heard about the issues dogging the regulation of biosimilar medicines in the Eastern Mediterranean Region, including unfamiliarity with the comparability exercise and a lack of expertise and resources in this area. The question of a "global comparator product" was also raised.

You may also be interested in...

WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars

Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.

Firms Advised To Prepare Now For New EU Patent System

After many delays and disagreements, Europe’s Unified Patent Court is expected to open its doors in the first quarter of 2023, offering a more cost-effective option for patent protection and dispute settlement in the EU. The new system includes the possibility of taking out a “unitary patent” offering EU protection in practically all the EU member states. A guide to the key points of the new system is shown below.

All Eyes On Rwanda As Africa Builds Up Regulatory & Manufacturing Abilities

The small central African country has been chosen to host the planned African Medicines Agency and is also set to be a key player in medicines and vaccines manufacturing technology on the continent.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts